Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNDX save search
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Published: 2024-04-10 (Crawled : 20:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 0.45%
H: 1.54%
C: 0.95%
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -1.34%
gment-101 positive leukemia trial
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 20:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
| Email alert
Add to watchlist
nasdaq pharmaceuticals grants
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 0.48%
H: 4.36%
C: 2.67%
gment-101 leukemia trial
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Published: 2024-03-28 (Crawled : 10:00) - globenewswire.com
ZYME | $8.555 -0.06% -0.06% 590K
|
Health Technology
|
| O: 0.49%
H: 2.13%
C: 1.64%
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 0.48%
H: 4.36%
C: 2.67%
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 1.24%
H: 0.24%
C: -0.39%
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Published: 2024-03-26 (Crawled : 20:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 1.63%
H: 6.7%
C: 5.87%
fda review treatment leukemia
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.64%
H: 0.77%
C: -6.2%
commercial
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
| Email alert
Add to watchlist
nasdaq pharmaceuticals grants
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Published: 2024-02-27 (Crawled : 21:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -1.23%
H: 5.1%
C: -0.95%
business year update pharmaceuticals financial results
Syndax Announces Participation at Two Upcoming Investor Conferences - February 26, 2024
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.09%
H: 5.8%
C: 5.47%
Syndax Announces Participation at Two Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 12:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.09%
H: 5.8%
C: 5.47%
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
Published: 2024-02-20 (Crawled : 00:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.45%
H: 5.77%
C: 2.24%
conference financial results
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-02-02 (Crawled : 21:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
| Email alert
Add to watchlist
nasdaq pharmaceuticals grants
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.23%
H: 0.32%
C: -3.48%
conference presentation
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
Published: 2024-01-02 (Crawled : 12:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -1.62%
H: 5.17%
C: 2.82%
Syndax Announces Pricing of $200 Million Public Offering of Common Stock - December 15, 2023
Published: 2023-12-15 (Crawled : 08:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 1.71%
H: 3.36%
C: 2.72%
offering
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
Published: 2023-12-15 (Crawled : 05:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 1.71%
H: 3.36%
C: 2.72%
offering
Syndax Announces Proposed $150 Million Public Offering of Common Stock
Published: 2023-12-14 (Crawled : 21:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 1.71%
H: 3.36%
C: 2.72%
offering
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
Published: 2023-12-12 (Crawled : 17:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -0.56%
H: 1.57%
C: -0.95%
gment-101 presentation positive meeting leukemia trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.